10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience. Javaid A, Peres T, Schmitt AM, Larkin J, et al. Int J Cancer 2026 Jul 9. doi: 10.1002/ijc.70653.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Javaid A, Peres T, Schmitt AM, Larkin J, et al. 10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience. Int J Cancer 2026 Jul 9. doi: 10.1002/ijc.70653.
PMID: 42426954